Showing 4861-4870 of 6036 results for "".
- ScienceBased Health Announces New Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/ScienceBased Health (SBH) announced the formation of its new Ophthalmology Clinical Advisory Panel that will provide insight and recommendations on eye care industry trends and new developments. In addition, it will help guide and support the company’s educational initiatives in the ophthalmology
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- Scientists Unravel the Function of a Sight-Saving Growth Factorhttps://modernod.com/news/scientists-unravel-the-function-of-a-sight-saving-growth-ffactor/2479302/Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-r
- The Vision Council Releases Results of the 2020 Internet Influence Reporthttps://modernod.com/news/the-vision-council-releasese280afresults-of-the-2020-internet-influence-report/2479298/The Vision Council has released the results of the “Internet Influence Report.” Conducted in December 2020, the special interest consumer report examines the role of the Internet among consumers who recently purchased different types of eyewear. The Vision Council fielded
- Biogen Fails to Meet Primary or Secondary Endpoints in Phase 3 Gene Therapy Study in Choroideremiahttps://modernod.com/news/biogen-fails-to-meet-primary-or-secondary-endpoints-in-phase-3-gene-therapy-study-in-choroideremia/2479291/Biogen announced topline results from the phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement fr
- Schwind Receives “SME Innovation Award“ in Germanyhttps://modernod.com/news/schwind-receives-sme-innovation-award-in-germany/2479288/Schwind eye-tech-solutions is one of the most innovative small and medium sized enterprises (SMEs) 2021/2022, according to a survey conducted by the independent Deutsche Gesellschaft für Verbraucherstudien (DtGV) in
- EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Studyhttps://modernod.com/news/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study/2479289/EyeGate Pharmaceuticals announced the first patient dosed in phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an in
- Reed Exhibitions Unveils New Brand Identityhttps://modernod.com/news/reed-exhibitions-unveils-new-brand-identity/2479287/Reed Exhibitions announced its evolution to RX, with a refreshed visual identity and updated brand positioning, according to The Vision Council. Building on its flagship events business, the company is leveraging its capabilities in data and technology to create